Eular 2025 PsA Topic Panel

Save

Eular 2025 PsA Topic Panel by Dr. Cush

EULAR 2025 – RA Panel Discussion

Save

Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care.

EULAR2025 Topic Podcast IL-17

Save

Efficacy and Safety of Xeligekimab in AS Sonelokimab in PsA Seronegative Arthritis Breakthroughs Novel Therapies in Axial Spondyloarthritis

EULAR2025 Topic Podcast RA2

Save

JAK Inhibitors: The Latest from the JAK-pot Study Does Abatacept Buy You Time Off RA? How to Properly Use Steroids in Early RA: Oral vs Parenteral All Rheumatoid Arthritis is Not the Same Jekyll and Hyde: which RA-ILD is it? RA treatment: A Constant State of Evolution

EULAR2025 Topic Podcast RA1

Save

Who/When to Treat Clinically Suspect Arthralgia Thoughtful, Effective RA Care Should be Guided by Need —Not Age The Impact of Biologics on Methotrexate Adherence Jokes Aside: The Impact of Laughter in RA JAK Safety Update Why is RA Difficult to Treat? DMARD Combinations in RA Treatment Increased Risk of VTE in RA: Lessons Learned from 40 Years of D

EULAR2025 Topic Podcast SpA

Save

Efficacy and Safety of Xeligekimab in AS Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-axSpA Emerging Therapies in Axial Spondyloarthritis Chronic Pain in AxSpA Beyond Fibromyalgia Novel Therapies in Axial Spondyloarthritis GLP 1 Receptor Agonists in axSpA Patients

EULAR2025 Topic Podcast PsA 2

Save

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact

EULAR2025 Topic Podcast PsA 1

Save

EULAR 2025 - Day 1 podcasts Sonelokimab in PsA Seronegative Arthritis Breakthroughs Using Combination csDMARDs in PsA Deucravacitinib's Place in the PsA Treatment Algorithm?

EULAR 2025 - Day 5 podcast

Save

Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact GLP 1 Receptor Agonists in axSpA Patients Jekyll and Hyde: which RA-ILD is it? RA treatment: A Constant State of Evolution

EULAR 2025 - Day 4 podcast

Save

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Emerging Therapies in Axial Spondyloarthritis Chronic Pain in AxSpA Beyond Fibromyalgia Novel Therapies in Axial Spondyloarthritis JAK Inhibitors: The Latest from the JAK-pot Study Does Abatacept Buy You Time Off RA

Daily Eular 2025 Recap Day 4

Save

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the fourth day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.

EULAR 2025 - Day 3 podcast

Save

Deucravacitinib's Place in the PsA Treatment Algorithm? Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-axSpA JAK Safety Update Why is RA Difficult to Treat? DMARD Combinations in RA Treatment Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data ALTO: Long-term Outcomes of APIP